Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549555 | 0.95 | KCNH2 (0.42) | KCNH2SCN5ALMNA | |
| SCHEMBL20549424 | 0.93 | SCN5A (0.49) | KCNH2SCN5ALMNA | |
| SCHEMBL20549374 | 0.88 | SCN5A (0.50) | KCNH2SCN5ALMNA | |
| SCHEMBL20549390 | 0.81 | SCN5A (0.48) | KCNH2SCN5ALMNA | |
| SCHEMBL20549416 | 0.81 | KCNH2 (0.52) | KCNH2SCN5A | |
| SCHEMBL20551914 | 0.81 | KCNH2 (0.52) | KCNH2SCN5A | |
| SCHEMBL20549420 | 0.81 | SCN5A (0.48) | KCNH2SCN5ALMNA | |
| SCHEMBL17494299 | 0.80 | KCNH2 (0.58) | KCNH2SCN5A | |
| SCHEMBL17494347 | 0.79 | SCN5A (0.69) | KCNH2SCN5A | |
| SCHEMBL20549509 | 0.76 | KCNH2 (0.55) | KCNH2SCN5ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | KCNH2 2920/4885SCN5A 1467/4885LMNA 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.